jRCT2080221765已完成2 期
NMK36 late phase II. Open-label study to assess efficacy and safety of a single dose (i.v.) of NMK36 in patients with prostate cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- safety
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Non-randomized, open-label, uncontrolled
- 主要目的
- Diagnostic Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- Male
入选标准
- •Patients with biopsy-proven prostate cancer.
- •Patients who are to have radical prostatectomy or hormone treatment.
排除标准
- •Patients with treated prostate cancer.
- •Patients with active double cancer.
- •Patients with bone-marrow, hepatic or renal dysfunction.
结局指标
主要结局
safety
Safety: subjective/objective symptoms, electrocardiogram exams, vital signs, laboratory tests
efficacy
Efficacy: diagnostic accuracy of regional lymph node metastases
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Phase II open-label pilot study to assess the effects of Testosterone Metered Dose Transdermal System (MDTS) administration on cognitive function in womecognitionNeurological - Other neurological disordersACTRN12608000429358FemPharm Pty Ltd10
进行中（未招募）
1 期
The purpose of the research study is to determine if domatinostat in combination with avelumab will be able to delay or prevent worsening of the disease in patients with advanced unresectable/metastatic Merkel Cell Carcinoma that is continuing to grow after previous anti-PD-(L)1 antibody therapy. Furthermore, safety of the combination during the study conduct will be assessed.patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD(L)1 antibody therapyMedDRA version: 21.1Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 100000004864EUCTR2018-004788-30-FR4SC AG40
进行中（未招募）
1 期
The purpose of the research study is to determine if domatinostat in combination with avelumab will be able to delay or prevent worsening of the disease in patients with advanced unresectable/metastatic Merkel Cell Carcinoma that is continuing to grow after previous anti-PD-(L)1 antibody therapy. Furthermore, safety of the combination during the study conduct will be assessed.EUCTR2018-004788-30-NL4SC AG40
进行中（未招募）
1 期
A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 studyEUCTR2018-004788-30-IT4SC AG40
已完成
2 期
A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD(L)1 antibody therapy - the MERKLIN 2 studyMerkel Cell Carcinoma (MCC)10040900NL-OMON490714SC AG4